
Overview
Inventro combines AI models with experimental biology for oncology drug discovery. It predicts molecular targets and ranks compounds for follow-up, then uses laboratory experiments to measure compound activity and cellular responses. Its scientists interpret the evidence to help research teams decide what to advance, retest or stop.
Financials
Revenue history (in k)
From the notes
| Profit allocation | Loss covered | |
| Loans and borrowings | $349,824 | |
| Revenue structure | usługi | |
| R&D costs | $112,092 | |
| Events after the balance sheet date | Yes | |
| Shareholders |
|
Filing timeliness
2 of 3 financial statements were filed late (the longest delay 308 days for 2023). All were audited by a statutory auditor.
- 202514/10/2026
- 202406/06/2025
- 202319/05/2025
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Molecular target prediction
- Compound prioritisation
- Compound activity testing
- Cellular response testing
- High-content imaging
- Experimental validation
Websites
The site is available in: Polish and English.
- inventro.coINVENTRO | AI-enabled oncology drug discoveryLLiteSpeed
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board is authorised independently to represent the company. In the case of a multi-member management board being appointed, joint action of two members of the management board or one member of the management board jointly with a commercial proxy is required to represent the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-03-01.
39 1090 2590 0000 0001 5233 9929
12 1090 2590 0000 0001 5233 9930
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 28, 2025 | Aid for research and development projects: industrial research | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| May 28, 2025 | Aid for research and development projects: experimental development | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-01 | High-throughput, multiparametric platform for testing drug candidates and drugs using ex vivo tumor models | $2.1M$2,144,730 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Digital Pathology Team sp. z o.o. | $64,552.91 | digitalpathologyteam.com | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| Onconick sp. z o.o. | $39,587.95 | onconick.com | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| Cannamedai S.A. | $28,203.90 | cannamedai.com | ||
| Pioligon sp. z o.o. | $29,597.16 | pioligon.pl | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Nanovelos S.A. | $24,842.03 | nanovelos.com | ||
| Skinai sp. z o.o. | $11,914.59 | skinai.pl | ||
| Oncotherics Poland S.A. | $7,565.33 | oncotherics.com |
FAQ
Last updated: 2026-10-14